Techcyte, leader in AI-powered digital pathology, announced today the first European clinical implementation of its Techcyte SureView™ cervical  cytology solution at Tyrolpath, one of the largest private pathology laboratories in Austria. In partnership with BD, Techcyte’s exclusive global  distributor for Techcyte SureView™ , this milestone marks a significant advancement in the digital transformation of cervical cancer screening in  Europe.

Tyrolpath, located in Zams, Austria, processes hundreds of thousands of Pap smears annually. To manage this volume, and lay the foundation for  future diagnostic applications, Tyrolpath acquired the Pramana Spectral HT-4 scanner — the only open, multipurpose whole slide imaging system  to offer smart, inline, volumetric scanning, providing high-throughput capacity, redundancy, and the flexibility to support multiple indications. The  lab has integrated Techcyte’s SureView™ platform alongside BD’s SurePath™ liquid-based cytology, creating an automated, end-to-end cervical  cancer screening workflow from sample collection through digital review.

“We are thrilled to see Tyrolpath leading the way in Europe,” said Ben Cahoon, Chief Executive Officer of Techcyte. “Dr. Obrist and his team are  pioneers in adopting new technologies to advance patient care, and we are proud to support their vision with our AI-driven solutions.”

Dr. Peter Obrist, owner of Tyrolpath and a key opinion leader in cytology, remarked,

“SureView™ brings a new level of confidence to cervical screening. The combination of BD SurePath™ preparation, Pramana’s high-quality imaging, and Techcyte’s AI analysis enables us to maintain the  highest diagnostic standards while preparing for the future of digital pathology.”

Sandra Knöthig, Product Manager Women’sHealth & Cancer C&EE from BD added,

“This collaboration marks an important step in the evolution of  cervical cancer screening. Our partnership with Techcyte and Tyrolpath demonstrates how innovation can be scaled to meet the needs of high-volume laboratories while laying the groundwork for broader diagnostic applications.”

This implementation reflects a growing interest across Europe in modernizing cytology workflows through integrated, digital solutions. As partners  explore the broader potential of AI and automation in laboratory diagnostics, this collaboration serves as an example of how technology and  expertise can come together to support the evolving needs of clinical practice.

About Techcyte

Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools  that aim to improve the efficiency and accuracy of diagnostic testing.

Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence.

We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified anatomic and clinical pathology platform to labs and clinics around the world.

Techcyte’s anatomic and clinical pathology platform is for Research Use Only in the United States.